Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators
Corcept Therapeutics Incorporated
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/985,035, filed Apr 28, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,047,082 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force · High confidence UsedRemaining | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 10,323,034 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 10,787,449 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 11,560,379 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 12,139,486 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 11,370,789 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| Application 18/906,346 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators Pending Not granted | Corcept Therapeutics, Inc. | Pending | Not granted | ||
| Application 16/036,001 | Octahydro Fused Azadecalin Glucocorticoid Receptor Modulators Abandoned Abandoned Jul 7, 2020 | Corcept Therapeutics, Inc. | Abandoned | Abandoned Jul 7, 2020 |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
6 of these are in force and held by Corcept Therapeutics Incorporated.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.